I-DynamX Bioadaptor iyikilasi elisha lokwelapha I-Coronary Artery Disease.
ISINGAPORE, Januwari 28, 2021 /EINPresswire.com/ — Imiphumela Yomtholampilo Yezinyanga ezingama-24 ye-Elixir Medical ye-DynamX I-Bioadaptor Iboniswe Iphrofayela Eqinile Yokuphepha, Ingenayo Imicimbi Yomtholampilo
U-Elixir Medical, umthuthukisi wemishini yenhliziyo nemithambo yegazi, edla izidakamizwa, umemezele imiphumela yomtholampilo yezinyanga ezingama-24 ye-DynamX™ Coronary Bioadaptor System, esanda kwethulwa engqungqutheleni yama-30 Yaminyaka Yonke Yokungenela I-Vascular Endotherapy ehlelwe yiNational Heart Center yaseSingapore (eSingapore. BUKHOMA). I-bioadaptor iyisimila sokuqala se-coronary artery esivumelana ne-body physiology.
Isifo se-artery Coronary (CAD) iwuhlobo oluvamile lwesifo senhliziyo. Kwenzeka lapho imithambo yenhliziyo iba mincane noma ivalwe ngoqweqwe loqwembe, okuncisha imisipha yenhliziyo umoya-mpilo nezakhi ezidingekayo. Odokotela ngokwesiko baye batusa ukusebenzisa i-drug-eluting stent (DES) ukuze kuvuleke imithambo yegazi emincane. Ama-stents ezidakamizwa yenza umsebenzi ophumelelayo osekela i-coronary artery kodwa i-cage unomphela umkhumbi, oye wahlotshaniswa nezenzakalo ezinkulu ezimbi zenhliziyo (MACE) .1 Lezi zenzakalo ezimbi ziqhubeka nokwakha unyaka nonyaka ngaphandle kokuphela.2
I-DynamX Bioadaptor iyikilasi elisha lokwelashwa kwe-CAD. Ngokungafani ne-DES, eqinile futhi ecindezela i-artery, i-bioadaptor iklanyelwe ukuhamba ngokwemvelo ngodonga lwe-artery ukuphendula izidingo zomoya-mpilo owengeziwe ofunwa yinhliziyo (njengesikhathi sokuzivocavoca). Iphinde ivumele umthambo ukuba ande ukuze uvumelane nanoma yikuphi ukwakheka koqweqwe olusha, ukugcina ububanzi bendawo eselashiwe ukuze kugeleze kahle igazi ngokuhamba kwesikhathi.3
UDkt Antonio Colombo, MD, umphenyi oyinhloko wocwaningo, uProfesa weCardiology e-Humanitas Medical School, u-Senior Consultant in Interventional Cardiology at Humanitas Research Hospital, Rossano, Milan, kanye noMqondisi weCardiac Catheterization Laboratory eColumbus Hospital, eMilan, I-Italy, iveze ukuthi imiphumela yezinyanga ezingama-24 yocwaningo lomtholampilo ikhombisile:
• iphrofayili yokuphepha enhle kakhulu ye-bioadaptha
• akukho ukuguqulwa komkhumbi okuhlosiwe
• akukho thrombosis yedivayisi (ukujiya kwegazi)
Idatha eshicilelwe ngaphambilini ku-bioadaptor ikhonjisiwe:3
• ikhono le-bioadaptor nomthambo wokunwebeka nokugcina umkhumbi uvulekile, okugcina ukugeleza kwegazi okuhle ngokuhamba kwesikhathi,
• ukunyakaza komthambo okuvamile ngokushaya kwenhliziyo ngakunye, okwenza umthambo unikeze ukugeleza kwegazi okwengeziwe ngokusabela ezidingweni zomzimba ngesikhathi sokusebenza ngokomzimba,
• ikhono ledivayisi kanye nokumbozwa kwezidakamizwa ukuvimbela ukuqhubeka kwesifo nokusekela umkhumbi ngesikhathi sokuphulukiswa.
UDkt. Colombo uthe, “Imithambo ye-Coronary ngokwemvelo inamandla okukhula ngokukhula kwesifo ukuze kugcinwe ukugeleza kwegazi enhliziyweni. Ama-stents akhipha izidakamizwa avala imithambo yenhliziyo futhi avimbele lokhu kusabela komzimba. I-DynamX iwukufakelwa kwensimbi yokuqala ye-coronary artery ukukhombisa ukulungiswa kabusha okuguquguqukayo komkhumbi. Ezinyangeni ze-24, i-bioadaptor yaqhubeka ingabonisi i-thrombosis futhi ingekho i-revascularization yomkhumbi ohlosiwe, okubonisa iphrofayili eqinile yokuphepha nokusebenza okuhle kakhulu. "
E-Singapore, isifo senhliziyo nemithambo yegazi sabalelwa ku-29.3% wabo bonke abashonile ngo-2019, ngokusho kweSingapore Heart Foundation.4 Lokhu kusho ukuthi cishe oyedwa kwabathathu abashonile kungenxa yesifo senhliziyo noma unhlangothi. I-National Heart Center yaseSingapore okwamanje isebenzisa i-DynamX Bioadaptor ezigulini zayo. Engqungqutheleni yaseSingapore LIVE, uProf. Lim Soo Teik wenze icala lesiguli bukhoma eSikhungweni Senhliziyo Kazwelonke esebenzisa i-DynamX Bioadaptor.
USolwazi Jack Tan, iPhini leNhloko kanye noMeluleki Omkhulu, uMnyango Wezempilo, iNational Heart Centre yaseSingapore, kanye neNhloko Yezifo Zenhliziyo, eSengkang General Hospital, uthe: “Ama-stents akhipha izidakamizwa ayindlela yokwelapha esezingeni legolide, kodwa likhona ithuba ngcono kulobo buchwepheshe. Isithembiso se-bioadaptor sisekubhekaneni nezinga elibi lika-2-3% esenzeka nge-DES unyaka ngamunye, okungase kuthuthukise imiphumela yesiguli yesikhathi eside. Siyajabula ukunikeza ubuchwepheshe bamuva obunamandla okunikeza izinzuzo ezinkulu ezigulini.”
USolwazi Lim Soo Teik, iPhini Lomqondisi Wezokwelapha kanye Nomeluleki Omkhulu, uMnyango Wezempilo, kanye noMqondisi weCardiac Catheterisation Laboratory, iNational Heart Centre Singapore, uthe, “I-DynamX Bioadaptor ibonise imiphumela emihle kakhulu yomtholampilo, futhi yenze kahle ohlelweni lwethulwa esibhedlela. Singapore LIVE inkomfa. Sithemba ukuthi ukuvumela umthambo ukuba wande, ulondoloze ukugeleza kwegazi, nokubuyisela ukunyakaza komthambo kungase kuphumele emiphumeleni engcono ezigulini zethu.”
Isiphetho: Imiphumela yocwaningo lomtholampilo lwezinyanga ezingama-24 ibonise izici ezinhle zephrofayili yokuphepha ye-DynamX Bioadaptor, ukufakelwa kwe-coronary artery yokuqala evumelana ne-physiology yomkhumbi.
1. Stone GW, Kimura T, Gao R, et al. Imiphumela Eshintshashintsha Isikhathi Nge-Absorb Bioresorbable Vascular Scaffold Phakathi Neminyaka engu-5 Yokulandela: Ukuhlaziywa Kwe-Meta Okuhlelekile kanye Nocwaningo Oluhlanganisiwe Lwedatha Yesiguli Ngasinye. JAMA Cardiol. 2019;4(12):1261–1269. doi:10.1001/jamacardio.2019.4101
2. Kufner S, Joner M, Thannheimer A, Hoppmann P, Ibrahim T, Mayer K, et al. Imiphumela yomtholampilo yeminyaka eyishumi evela ekuhlolweni kwama-stents amathathu e-limus-eluting anezingubo ze-polymer ezihlukene ezigulini ezine-coronary artery disease: imiphumela evela ku-ISAR-TEST 4 yokuhlola okungahleliwe. Ukujikeleza. 2019; 139:325–333. doi: 10.1161/CIRCULATIONAHA.118.038065.
3. Verheye S, Vrolix M, Montorfano M, Zivelonghi C, Giannini F, Bedogni F, et al. Imiphumela yezinyanga eziyishumi nambili yomtholampilo neyokucabanga ye-uncaging coronary DynamX bioadaptor. I-EuroIntervention 2020;16;e974-e981.
4. https://www.myheart.org.sg/my-heart/heart-statistics/singapore-statistics/
- Qeda -
Mayelana ne-Elixir Medical Corporation
I-Elixir Medical Corporation, inkampani exhaswe ngasese esekelwe eMilpitas, eCalifornia, ithuthukisa izinhlelo zesizukulwane esilandelayo zokwelapha isifo se-coronary artery eziklanyelwe ukubuyisela ukunyakaza okujwayelekile kwe-pulsatile kanye nekhono lokulungisa kabusha i-adaptive yomkhumbi wegazi. Umgomo wenkampani ukuguqula ukunakekelwa kweziguli ezinesifo senhliziyo nemithambo yegazi ngokusebenzisa izinto ezintsha. Ukuze uthole ukwaziswa okwengeziwe mayelana Elixir Medical Corporation, vakashela: https://elixirmedical.com/international/about-us/.
I-DynamX Coronary Bioadaptor System igunyaziwe yi-CE Mark. Ayitholakali ukuthi ithengiswe e-USA.
# # #
Ngeminye imininingwane, sicela uthinte: -
Inkampani Mileage Communications Pte Ltd
Patsy Phay / Eumund Tan
Ucingo: 6222-1678 / Iselula: 9640-5118 / 9129 3320
Email: [i-imeyili ivikelwe] / [i-imeyili ivikelwe]
www.mileage.com.sg
Patsy Phay
Inkampani Mileage Communications Pte Ltd
62221678
thumela i-imeyili lapha
Sivakashele ezinkundleni zokuxhumana:
Facebook
I-LinkedIn
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- 3• the ability of the bioadaptor and artery to expand and keep the vessel open, which preserves good blood flow over time,• normal artery motion with each heartbeat, enabling the artery to provide more blood flow in response to the body's needs during physical activity,• the ability of the device and its drug coating to inhibit disease progression and support the vessel during healing.
- Unlike DES, which are rigid and constrain the artery, the bioadaptor is designed to move more naturally with the artery wall in response to the needs for more oxygen demanded by the heart (such as during exercise).
- Antonio Colombo, MD, co-principal investigator of the study, Professor of Cardiology at Humanitas Medical School, Senior Consultant in Interventional Cardiology at Humanitas Research Hospital, Rossano, Milan, and Director of the Cardiac Catheterisation Laboratory in Columbus Hospital, Milan, Italy, revealed that the 24-month results from the clinical study showed.
